Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Brazil / NCT07581873
Active, not recruiting Not applicable

Education and Health in Women With Cervical Cancer

NCT07581873 · tracked via the Priya Life Science Brazil tracker
Phase
Not applicable
Started
2025-05-20
Last updated
2026-05-14

Condition(s) studied

Cervical CancerCervical Cancer ScreeningCervical Cancer Prevention

Investigational drug(s) / intervention(s)

Health Education Recommendations Group

Health Education Recommendations Group: In the first meeting, participants will answer a questionnaire called "Sociodemographic and Clinical Profile of Participants," designed to collect essential information about their social characteristics and clinical conditions. After this stage, each participant will receive a detailed booklet containing all the axes of the Education on Health program, which are: Sedentary Behavior, Physical Activity, Healthy Eating, Mental Health (Self-esteem, Self-care and Body Image), Socialization, Physical Health (Illness, Sleep and Hydration). During the 12 weeks of the study, participants will receive periodic recommendations on all the aforementioned themes through messages sent via WhatsApp. Complementary online meetings will also be held for each theme, promoting group activities designed to encourage the exchange of experiences, collaborative learning, and the development of healthy habits.

Study summary

Introduction: Cervical neoplasms constitute a significant public health problem on a global scale. According to the National Cancer Institute, this pathology is the third most prevalent type of cancer among women in Brazil, and the second most incident neoplasm in the North and Northeast regions. Estimates for each year of the 2023-2025 triennium point to approximately 17,010 new cases, with a gross incidence rate of 15.38 cases per 100,000 women. Health education emerges as a fundamental strategy in promoting healthy behaviors and building critical awareness of the health-disease process, considering individual and collective particularities.

Objective: To evaluate the effect of health education on the level of quality of life, physical activity, self-esteem, anxiety, depression, nutrition, and pain in women with cervical cancer.

Materials and Methods: This is a clinical trial with cervical cancer patients. The sample will be randomly distributed into two groups: the Health Education Recommendations Group (HERG) and the Control Group (CG), which will remain under usual care. The intervention will last 12 weeks, during which the HERG will receive health education recommendations through face-to-face meetings and via social media. The variables in this study are the participants' sociodemographic and clinical profile, lifestyle, sedentary behavior, level of physical activity, nutrition, self-esteem, anxiety and depression, quality of life, and pain. The variables of interest will be evaluated at baseline, after 6 and 12 weeks through multivariate analysis, comparing the effects of group, time, and interaction of both. Analyses will be performed using SPSS version 24.0 software, with a significance level of 5%. Expected results: Lifestyle change in at least two addressed areas. The developed material contributes to the scientific literature through the creation of textbooks, articles, and by offering valuable insights into the effectiveness of health education strategies. Future research can expand this work, adapting it to other populations or contexts to maximize its impact.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Women aged 18 or older; * Diagnosed with cervical cancer; * Undergoing cervical cancer treatment (chemotherapy, radiotherapy, and/or hormone therapy); * Having daily access to a smartphone. Exclusion Criteria: * Having another type of cancer; * Undertake physical training for three months prior to the intervention; * Have a medical contraindication to perform any type of physical activity; * Have a "yes" answer on the PAR-Q and a medical contraindication; * Not be mentally capable of using a smartphone or answering the research questionnaires;

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Federal University of Maranhão São Luís Maranhão

More Federal University of Maranhao trials in Brazil

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07581873 on ClinicalTrials.gov ↗ ← All trials in Brazil